Applied DNA Sciences, Inc. (APDN)

Applied DNA Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	-13.19	-6.99	-9.95	-8.27	-14.29	-13.03
Depreciation & Amortization	0.56	0.7	1.36	1.29	0.84	0.29
Other Amortization	-	-	-	-	-	0.03
Loss (Gain) From Sale of Assets	-	-	-0.01	-	0.21	-
Asset Writedown & Restructuring Costs	0.01	-	0.06	-	0.82	-
Stock-Based Compensation	0.11	0.57	1.03	2.52	1.67	1
Provision & Write-off of Bad Debts	0.01	-	-0.24	0.27	0.03	0.05
Other Operating Activities	-0.28	-6.85	-0.93	-5.74	0.94	-0
Change in Accounts Receivable	0.16	-0.11	3.05	-0.53	-2.64	0.6
Change in Inventory	0.13	-0.11	0.27	0.77	-0.87	-0.35
Change in Accounts Payable	-0.21	-0.48	-1.35	0.93	0.09	0.43
Change in Unearned Revenue	0.05	-0.02	-0.29	0.28	-0.23	-0.12
Change in Other Net Operating Assets	-0.01	-0.43	0.77	-0.49	0.03	-0.03
Operating Cash Flow	-12.58	-13.71	-6.22	-8.98	-13.39	-11.14
Capital Expenditures	-0.68	-0.41	-1.14	-0.49	-2.55	-1.06
Sale of Property, Plant & Equipment	-	-	0.05	-	-	-
Investing Cash Flow	-0.66	-0.41	-1.1	-0.49	-2.55	-1.06
Long-Term Debt Issued	-	-	-	-	-	0.85
Total Debt Issued	-	-	-	-	-	0.85
Long-Term Debt Repaid	-	-	-	-	-1.67	-0.11
Net Debt Issued (Repaid)	-	-	-	-	-1.67	0.74
Issuance of Common Stock	7.54	13.4	-	18.13	16.37	18.7
Financing Cash Flow	7.54	13.4	-	18.13	14.7	19.43
Net Cash Flow	-5.7	-0.72	-7.31	8.66	-1.23	7.23
Free Cash Flow	-13.26	-14.12	-7.36	-9.47	-15.94	-12.21
Free Cash Flow Margin	-354.28%	-411.47%	-55.05%	-52.10%	-176.53%	-631.98%
Cash Interest Paid	-	-	-	-	-	0.05
Levered Free Cash Flow	-8.83	-9.04	-3.68	-4.48	-10.48	-7.17
Unlevered Free Cash Flow	-8.83	-9.04	-3.68	-4.48	-10.48	-7.12
Change in Working Capital	0.13	-1.14	2.45	0.95	-3.62	0.53

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q